Neurocrine Biosciences
American biopharmaceutical company
NBIX Nasdaq
ISIN US64125C1099 SEC CIK 914475 LEI 549300FECER0XBN49756
Follow Neurocrine Biosciences
Weekly email: filings, results
Revenue, last quarter
$1.1B
+41.2% vs same quarter last year
Net income
$206.5M
−1.4% vs same quarter last year
EPS, diluted
$1.96
−3.9% vs same quarter last year
Operating cash flow
$395.2M
+73.7% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $2.9B | $478.6M |
| FY24 | $2.4B | $341.3M |
| FY23 | $1.9B | $249.7M |
| FY22 | $1.5B | $154.5M |
| FY21 | $1.1B | $89.6M |
| FY20 | $1B | $407.3M |
| FY19 | $788.1M | $37M |
| FY18 | $451.2M | $21.1M |
| FY17 | $161.6M | −$142.5M |
| FY16 | $15M | −$141.1M |
| FY15 | $19.8M | −$88.9M |
| FY14 | $0 | −$60.5M |
| FY13 | $2.9M | −$46.1M |
| FY12 | $53.1M | $5M |
| FY11 | $77.4M | $37.6M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | 98.2% | 21.6% | 16.7% |
| FY24 | 98.6% | 24.2% | 14.5% |
| FY23 | 97.9% | 13.3% | 13.2% |
| FY22 | 98.4% | 16.7% | 10.4% |
| FY21 | 98.7% | 9% | 7.9% |
| FY20 | 99% | 15.6% | 38.9% |
| FY19 | - | 9.2% | 4.7% |
| FY18 | 98.9% | 8.2% | 4.7% |
| FY17 | 99.2% | −81.3% | −88.2% |
| FY16 | 100% | −982.5% | −940.6% |
| FY15 | 100% | −476.5% | −449.8% |
| FY14 | - | - | - |
| FY13 | - | −1701.9% | −1579% |
| FY12 | - | 2.7% | 9.5% |
| FY11 | - | 43.8% | 48.5% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | $748.7M |
| FY24 | $557.2M |
| FY23 | $361.6M |
| FY22 | $322.9M |
| FY21 | $233.1M |
| FY20 | $217.6M |
| FY19 | $132.3M |
| FY18 | $76.6M |
| FY17 | −$101.3M |
| FY16 | −$110.3M |
| FY15 | −$39.9M |
| FY14 | −$48.8M |
| FY13 | −$30.2M |
| FY12 | −$36.3M |
| FY11 | −$1.4M |
Show the numbers
| Year | Buybacks |
|---|---|
| FY25 | $167.7M |
| FY24 | $300M |
| FY23 | $0 |
| FY22 | $0 |
| FY21 | - |
| FY20 | - |
| FY19 | - |
| FY18 | - |
| FY17 | - |
| FY16 | - |
| FY15 | - |
| FY14 | - |
| FY13 | - |
| FY12 | - |
| FY11 | - |
- Neurocrine Biosciences
- Healthcare median
Show the numbers
| Year | Neurocrine Biosciences | Healthcare median |
|---|---|---|
| FY25 | 16.7% | −30.6% |
| FY24 | 14.5% | −47% |
| FY23 | 13.2% | −58% |
| FY22 | 10.4% | −80.4% |
| FY21 | 7.9% | −71.9% |
| FY20 | 38.9% | −62.2% |
| FY19 | 4.7% | −46.3% |
| FY18 | 4.7% | −49.6% |
| FY17 | −88.2% | −45.9% |
| FY16 | −940.6% | −36% |
| FY15 | −449.8% | −38.4% |
| FY14 | - | −35.5% |
| FY13 | −1579% | −37.1% |
| FY12 | 9.5% | −29.1% |
| FY11 | 48.5% | −27.9% |